BRWA
ABCL icon

B. Riley Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

B. Riley Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$1.64K – 916
2026
Q1 		$1.64K Buy
+50,000
New +$180K ﹤0.01% 891
2025
Q4 		– Sell
-50,000
Closed -$2.52K – 1021
2025
Q3 		$2.52K Buy
+50,000
New +$220K ﹤0.01% 1071

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
HOWA
Heritage Oak Wealth Advisors Santa Rosa Beach, Florida $340M AUM 29.73% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

B. Riley Wealth Advisors's ABCL Position: Q2 2026 in Review

B. Riley Wealth Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 500 shares — an estimated $1.64K sold.

B. Riley Wealth Advisors first reported a position in ABCL in Q3 2023 and held it in 7 quarters. The position peaked at $111K in Q4 2023. 27 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • B. Riley Wealth Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 500 AbCellera Biologics shares in Q2 2026, an estimated $1.64K.
  • B. Riley Wealth Advisors first reported a position in AbCellera Biologics in Q3 2023 and held it in 7 quarters.
  • B. Riley Wealth Advisors's AbCellera Biologics position peaked at $111K in Q4 2023.
  • 27 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.